Swedbank AB Takes $6.14 Million Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Swedbank AB purchased a new stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 67,520 shares of the company’s stock, valued at approximately $6,138,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of GEHC. Wynn Capital LLC lifted its stake in GE HealthCare Technologies by 4.1% in the first quarter. Wynn Capital LLC now owns 3,125 shares of the company’s stock worth $284,000 after purchasing an additional 122 shares during the last quarter. Byrne Asset Management LLC lifted its stake in GE HealthCare Technologies by 0.8% in the first quarter. Byrne Asset Management LLC now owns 16,424 shares of the company’s stock worth $1,493,000 after purchasing an additional 126 shares during the last quarter. WASHINGTON TRUST Co lifted its stake in GE HealthCare Technologies by 7.7% in the first quarter. WASHINGTON TRUST Co now owns 1,853 shares of the company’s stock worth $168,000 after purchasing an additional 133 shares during the last quarter. Fiduciary Trust Co lifted its stake in GE HealthCare Technologies by 1.8% in the fourth quarter. Fiduciary Trust Co now owns 7,696 shares of the company’s stock worth $595,000 after purchasing an additional 133 shares during the last quarter. Finally, Quent Capital LLC lifted its stake in GE HealthCare Technologies by 21.3% in the first quarter. Quent Capital LLC now owns 780 shares of the company’s stock worth $71,000 after purchasing an additional 137 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

GEHC has been the subject of several research analyst reports. Mizuho decreased their price target on shares of GE HealthCare Technologies from $110.00 to $105.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Bank of America decreased their price target on shares of GE HealthCare Technologies from $94.00 to $86.00 and set a “neutral” rating for the company in a research note on Wednesday, May 1st. Finally, The Goldman Sachs Group initiated coverage on shares of GE HealthCare Technologies in a research note on Thursday, May 30th. They set a “neutral” rating and a $87.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, GE HealthCare Technologies has a consensus rating of “Moderate Buy” and a consensus price target of $94.09.

Insider Transactions at GE HealthCare Technologies

In other news, CEO Jan Makela sold 66,955 shares of GE HealthCare Technologies stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $81.54, for a total transaction of $5,459,510.70. Following the completion of the sale, the chief executive officer now directly owns 63,348 shares in the company, valued at $5,165,395.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Jan Makela sold 66,955 shares of the business’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $81.54, for a total transaction of $5,459,510.70. Following the completion of the transaction, the chief executive officer now directly owns 63,348 shares in the company, valued at $5,165,395.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CTO Taha Kass-Hout sold 3,300 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $78.70, for a total transaction of $259,710.00. Following the transaction, the chief technology officer now owns 67,300 shares of the company’s stock, valued at $5,296,510. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 90,482 shares of company stock worth $7,369,137. Company insiders own 0.27% of the company’s stock.

GE HealthCare Technologies Stock Up 0.0 %

NASDAQ GEHC traded up $0.04 on Friday, hitting $83.44. The stock had a trading volume of 2,986,428 shares, compared to its average volume of 2,926,614. The business’s fifty day moving average price is $78.91 and its 200 day moving average price is $82.38. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.06 and a quick ratio of 0.83. GE HealthCare Technologies Inc. has a 52-week low of $62.35 and a 52-week high of $94.50. The stock has a market cap of $38.10 billion, a price-to-earnings ratio of 24.40, a price-to-earnings-growth ratio of 3.00 and a beta of 1.17.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings results on Wednesday, July 31st. The company reported $1.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.02. GE HealthCare Technologies had a net margin of 8.10% and a return on equity of 25.26%. The business had revenue of $4.84 billion for the quarter, compared to analyst estimates of $4.88 billion. During the same period in the previous year, the company earned $0.92 earnings per share. The business’s revenue for the quarter was up .5% on a year-over-year basis. Equities research analysts anticipate that GE HealthCare Technologies Inc. will post 4.27 earnings per share for the current year.

GE HealthCare Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 15th. Stockholders of record on Friday, July 19th will be paid a dividend of $0.03 per share. The ex-dividend date is Friday, July 19th. This represents a $0.12 annualized dividend and a dividend yield of 0.14%. GE HealthCare Technologies’s payout ratio is currently 3.51%.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.